Oligometastatic Disease and Interventional Oncology: Rationale and Research Directions

Cancer J. 2020 Mar/Apr;26(2):166-173. doi: 10.1097/PPO.0000000000000442.

Abstract

Oligometastatic disease (OMD) is generally defined as a stage of clinically or radiographically demonstrated metastatic disease limited in total disease burden and without rapid spread. Interventional oncology performs local therapies for primary and metastatic cancers, including OMD. Interventional oncology treatments can be pursued both as definitive therapy and for palliative purposes. Applied to OMD, these interventions can offer patients a decreasing overall tumor burden, minimizing cancer morbidity, and early evidence suggests a survival benefit. Here, we discuss the range of interventional oncology treatments, including ablation, chemoembolization, radioembolization, and irreversible electroporation. We describe the rationale for their application to OMD and discuss future directions for research.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Ablation Techniques / methods
  • Ablation Techniques / trends
  • Antineoplastic Agents / administration & dosage
  • Chemoembolization, Therapeutic / methods
  • Chemoembolization, Therapeutic / trends
  • Clinical Trials as Topic
  • Electrochemotherapy / methods
  • Electrochemotherapy / trends
  • Evidence-Based Medicine / methods*
  • Evidence-Based Medicine / trends
  • Humans
  • Medical Oncology / methods*
  • Medical Oncology / trends
  • Neoplasm Metastasis / therapy*
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Progression-Free Survival
  • Tumor Burden

Substances

  • Antineoplastic Agents